Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis

Ariad Pharmaceuticals (NASDAQ: ARIA  ) and Exelixis (NASDAQ: EXEL  ) have both stumbled, with bad news causing significant drops in share price over the past year (Ariad has lost over 60% of its value, while Exelixis is down 30% over the last year and over 60% from its 52-week high at the beginning of 2014).

Ariad had issues with its drug Iclusig, which was pulled from the market by the FDA due to safety issues, and has now returned with stronger warning labels and a reduced market potential. Investors were hoping that Exelixis' Cometriq, which is currently approved for thyroid cancer, would be so effective in a prostate cancer trial that the trial would be stopped early. That didn't happen.

With both stocks down badly from their 52-week highs, which is the better bad news buy?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson tell you which, and why.

Of course, there may be even better opportunities out there. Try this top stock on for size.
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (1) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2970655, ~/Articles/ArticleHandler.aspx, 9/2/2015 2:43:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated 5 hours ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 3:59 PM
ARIA $9.10 Down -0.35 -3.65%
Ariad Pharmaceutic… CAPS Rating: ***
EXEL $5.60 Down -0.35 -5.88%
Exelixis CAPS Rating: ****